Navigation Links
AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Date:3/11/2009

, except per share data) 2008 2007 2008 2007 2006 ------------------------------------------------------------------------- ------------------------------------------------------------------------- $ $ $ $ $ Revenues Sales and royalties 4,640 6,435 29,462 28,825 25,123 License fees 2,092 3,705 8,504 12,843 13,652 Other 512 100 512 400 24 ------------------------------------------------------------------------- 7,244 10,240 38,478 42,068 38,799 ------------------------------------------------------------------------- Operating expenses Cost of sales 4,930 3,255 19,278 12,930 11,270 Selling, general and administrative expenses 3,038 5,146 17,325 20,403 16,478 Research and development costs 12,328 13,574 57,448 39,248 27,422 R&D tax credits and grants (137) (1,941) (343) (2,060) (1,564) Depreciation and amortization Property, plant and equipment 316 378 1,515 1,562 2,816 Intangible assets 3,084 757 5,639 4,004 6,148 Impairment of long-lived asset held for sale - 735 - 735 - ------------------------------------------------------------------------- 23,559 21,904 100,862 76,822 62,570 ------------------------------------------------------------------------- Loss from operations (16,315) (11,664) (62,384) (34,754) (23,771) ------------------------------------------------------------------------- Other income (expenses) Interest income 1
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Appistry, Inc. ... that bring the power of genomics to next-generation medicine, ... Appistry Pipeline Challenge . , Two Appistry staff ... the National Center for Genome Resources, and Mr. Neil ... Clinics of Kansas City. Rounding out the panel are ...
(Date:7/28/2014)... -- Research and Markets has announced the addition ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... used to determine the size of a particle in a ... analyze the size of particles as it can affect the ... to determine the behavior and nature of a material, and ...
(Date:7/25/2014)... Trillions of bacteria live in each person,s digestive tract. ... food and stave off harmful infections, but their role ... help shed light on the role of these bacteria, ... Eric Alm recently tracked fluctuations in the bacterial populations ... findings, described in the July 25 issue of the ...
(Date:7/25/2014)... The Conferee Networking committee is pleased to ... These two-hour sessions provide a unique networking opportunity for ... discuss new techniques, or brainstorm new ideas in an ... for consideration is August 31, 2014, and instructions can ... committee will review the topics, and status notifications will ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Particle Size Analysis Market 2014-2018 2Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2
... THE WOODLANDS, Texas, Oct. 4 Lexicon,Pharmaceuticals, Inc. (Nasdaq: ... Ph.D., Lexicon,s president and chief executive officer, will present,at ... Francisco, California,on Thursday, October 11, 2007 at 11:00 a.m. ... may be accessed on its,corporate website at http://www.lexpharma.com ...
... Oct. 4 Genzyme Corp.,(Nasdaq: GENZ ) ... market,Elaprase(R) (idursulfase) in Japan for the treatment of ... by Shire Human Genetic,Therapies Inc., and Genzyme is ... countries under an agreement with Shire. Genzyme intends,to ...
... CLARA, Calif., Oct. 4 Coherent, Inc.,(Nasdaq: COHR ... 2007, it,received an additional NASDAQ Staff Determination letter indicating ... listing,requirements as set forth in Marketplace Rules 4350(e) and ... of stockholders during its fiscal,year ended September 30, 2007. ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at Bio InvestorForum 2Genzyme Receives Approval to Market Elaprase(R) in Japan 2Genzyme Receives Approval to Market Elaprase(R) in Japan 3Genzyme Receives Approval to Market Elaprase(R) in Japan 4Coherent, Inc. Receives Expected Letter from NASDAQ 2
(Date:7/28/2014)... for Biologically Inspired Engineering at Harvard University today ... commercialized by a newly formed private company to ... medicine products. The announcement follows a ... Development (OTD) and the start-up Emulate Inc., relating ... Organs-on-Chips platform. , "This is a big ...
(Date:7/27/2014)... nicotine and cotinine, a metabolite of nicotine, can potentially ... smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK is produced ... up in the tobacco smoke. Once inhaled, it is ... activated by a variety of enzymes called Cytochrome P450 ... can partially interfere with the activation of NNK, and ...
(Date:7/27/2014)... mayfly in the southern Western Ghats, a mountain range along ... first time that any mayfly belonging to the genus ... new species, called Labiobaetis soldani , "is named in ... the understanding of the Ephemeroptera of Palaearctic and Oriental realms," ... new mayfly in the Journal of Insect Science . ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2
... senior female family members should play a key role in ... societies. However, they are often overlooked by health organisations that ... as an obstacle to promoting good nutrition and health practices. ... review published in the January issue of Maternal and ...
... This press release is available in German . ... as tsunamis, landslides, and ground settlements, caused a damage of ... the so far highest economic losses due to earthquakes. This ... from the Center for Disaster Management and Risk Reduction Technology ...
... Springer celebrates its 50,000th eBook, available on ... milestone underscores Springer,s position as the largest eBook ... world,s most comprehensive online collection of science, technology ... In addition, as announced in October 2011, ...
Cached Biology News:Research highlights key role grandmothers play in mother and child nutrition and health 2Research highlights key role grandmothers play in mother and child nutrition and health 3Japan and New Zealand were hit hardest by earthquakes 2SpringerLink now offers more than 50,000 eBooks 2
... The Mini-PROTEAN 3 Dodeca cell with multi-casting ... of up to 12 mini format handcast (8.3 ... cm) gels. The cell requires 3.4-4.4 L of ... cooling coil that attaches to an external refrigerated ...
...
... has been developed to significantly increase the ... Stability is increased at room temperature ... This product is subjected to 0.2 ... azide. This formulation insures consistently high ...
...
Biology Products: